Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072096 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
A Phase 4 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 4
- Development phase
- 192
- Enrollment target
NCT02072096: Clinical Trial Phase 4 study, sponsored by Eli Lilly and Company.
NCT02072096 is a Phase 4 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 192 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02072096, a Phase 4 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 192 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM. One strategy is based on the use of oral and injectable medications that only reduce blood sugar (glucose) when it is high. The other strategy is based on non-glucose dependent agents. The trial will last up to 72 weeks for each participant.
Primary Outcome
Failed to reach and maintain HbA1c target, without clinically significant hypoglycemia, is defined as having 2 consecutive HbA1c \> upper limit of HbA1c target over 12 weeks starting from Week 24 for participants with HbA1c data beyond Week 24, or Week 24 HbA1c \> upper limit of HbA1c target for participants without HbA1c data beyond Week 24. Clinically significant hypoglycemia is defined as any severe hypoglycemia or repeated hypoglycemia interrupting participants activities or sleep and associ
Interventions
- DRUG Metformin
- DRUG Pioglitazone
- DRUG Linagliptin
- DRUG Glimepiride
- DRUG Acarbose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-10 |
| Phase | Phase 4 |
Why NCT02072096 stopped before completion
NCT02072096 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT02072096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02072096 about?
NCT02072096 is a clinical study titled "A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)". The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM. One strategy is based on the use of oral and injectable medications that only reduce blood sugar (glucose) when it i...
What is the current status of trial NCT02072096?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 192 participants. The study started on 2014-02. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02072096?
The interventions under investigation include: Metformin (DRUG), Pioglitazone (DRUG), Linagliptin (DRUG), Glimepiride (DRUG), Acarbose (DRUG).
Who is sponsoring clinical trial NCT02072096?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02072096's enrollment target sits among peer trials
192 451st of 2000 higher than 1,548 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia